You are here

Recursion Pharmaceuticals, LLC

Company Information
Address
383 Colorow Dr
Salt Lake City, UT 84108-1201
United States


http://www.recursionpharma.com

Information

UEI: K19FFWF23DK3

# of Employees: 9


Ownership Information

HUBZone Owned: Yes

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR-Success: Artificial Intelligence (AI) to Discover Therapies for Untreated Rare Diseases

    Millions of people suffer from at least one of thousands of rare diseases. Despite this fact, drug companies tend to focus on developing therapies for diseases that affect many people.“Rare disease by and large has more unmet needs than other diseases,” says Chris Gibson, co-founder...

Award Charts




Award Listing

  1. Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

    Amount: $1,391,082.00

    DESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of A ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  2. Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

    Amount: $223,006.00

    DESCRIPTION provided by applicant Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of A ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  3. HLS13-04 High-Content High-Throughput Screen for Diamond Blackfan Anemia Treatments

    Amount: $217,352.00

    DESCRIPTION provided by applicant There are thousands of rare genetic diseases that have no approved treatment Recursion Pharmaceuticals has developed a drug discovery platform that seeks to re p ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  4. Application of an efficient drug repurposing platform to identify treatments for Cornelia De Lange Syndrome

    Amount: $224,625.00

    DESCRIPTION provided by applicant Cornelia de Lange Syndrome is a complex congenital malformations syndrome with many post natal progressive medical complications CdLS has a clear genetic cause wi ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  5. Expansion of an efficient drug repurposing platform for rare genetic diseases.

    Amount: $1,459,171.00

    DESCRIPTION provided by applicant There are thousands of rare genetic diseases that have no approved treatment Recursion Pharmaceuticals has developed a drug discovery platform that seeks to re pu ...

    SBIRPhase II2015Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government